Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06734884
Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome) (BENRADRESS)
Efficacy and Safety of Anti-interleukin 5 Receptor Therapy (Benralizumab) in Patients With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)
Sponsor: AstraZeneca
Conditions
DRESS Syndrome
Interventions
Benralizumab 30 MG/ML [Fasenra] Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
Updated 2 times since 2025 Last updated: Jan 15, 2025 Started: Jan 6, 2025 Primary completion: Jan 5, 2029 Completion: Sep 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on DRESS Syndrome, this trial is actively recruiting participants. The trial is conducted by AstraZeneca and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Feb 2025 — Present [monthly]
Not Yet Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- AstraZeneca
- University Hospital, Lille
Data source: University Hospital, Lille
For direct contact, visit the study record on ClinicalTrials.gov .